The U.S. Food and Drug Administration (FDA) has given GT Biopharma a green light to start a Phase…
News
POLYCYTHEMIA VERA
Targeting inflammation may help control polycythemia vera
Inflammation plays a key role in the progression of polycythemia vera (PV), making it an important potential treatment target. In a new Perspective article,…
Artificial intelligence (AI) may help design better CAR T-cell therapies to treat myeloma and other cancers, a study showed. An AI-designed CAR…
PANCREATIC CANCER
Newly approved pancreatic cancer drug wins breakthrough therapy status
The U.S. Food and Drug Administration (FDA) has awarded its breakthrough therapy designation — which aims to speed the development of promising new medications —…
Treatment with Tecvayli (teclistamab), an approved cancer drug, can reduce the risk of disease progression in people with high-risk smoldering multiple myeloma, an…
The overall risk of any infection in the first year after starting treatment is similar in people given different types of immune-modulating therapies for…
Bristol Myers Squibb‘s experimental cell therapy arlocabtagene autoleucel (arlo-cel) may help control myeloma that has returned or failed…
A CAR T-cell therapy targeting glioblastoma improved tumor control and survival in mice when given before surgery rather than afterward, according to a new study.
September is Gynecologic Cancer Awareness Month, and advocacy groups are running campaigns to raise awareness about gynecological cancers, raise funds for research, and…
Since the late 1940s, when the first chemotherapies were introduced, advances in treatment for blood cancers have resulted in an estimated 25.8 million life-years…
Recent Posts
- Newly approved injection therapy gives PV patients a new option
- Inventing words for caregiving experiences no else understands
- New add-on therapy may help delay worsening in hard-to-treat myeloma
- US trial testing new med in combo with approved drug for pancreatic cancer
- The power of hope against a new multiple myeloma diagnosis